Premium
Nizatidine, an H 2 ‐Receptor Antagonist: Disposition and Safety in the Elderly
Author(s) -
Callaghan John T.,
Rubin Alan,
Knadler Mary Pat,
Bergstrom Richard F.
Publication year - 1987
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1987.tb03075.x
Subject(s) - disposition , antagonist , pharmacology , medicine , receptor antagonist , receptor , psychology , social psychology
Nizatidine is an orally active H 2 ‐receptor blocker. Its disposition and safety in eight young and 12 elderly volunteers were investigated. Single oral doses of nizatidine were administered: from 100 mg to 300 mg in the elderly, and from 100 mg to 350 mg in the young. The nizatidine AUC was directly proportional to dose for both groups. Calculated pharmacokinetic variables in the elderly vs. the young were t 1/2 = 1.9 vs. 1.6 hr; CL p /f = 32 vs. 40 L/hr, and Vd β /f = 1.2 vs. 1.3 L/kg. The impaired renal function of some elderly volunteers prolonged nizatidine elimination and lowered its clearance. Renal impairment rather than advanced age per se was the predominant factor in decreasing the nizatidine elimination rate. Because Cl cr correlated directly with nizatidine renal clearance, Cl cr values may be used to estimate nizatidine dosage reductions in renal insufficiency. During the trial, no serious adverse effects occurred.